علاج الميلانوما الأميلانوسيتية في الميلانوما الجلدية المرحلة IIIA–D المستأصلة مع طفرة BRAF (V600E/K)

References

• For patients with resected stage IIIA-D disease that is BRAF-mutant (V600E/K*), the following adjuvant therapy options should be offered (in no particular order): nivolumab 3 52 weeks OR pembrolizumab 3 52 weeks OR dabrafenib plus trametinib 3 52 weeks.
• Nivolumab 240 mg iv once every 2 weeks or once 480 mg iv once every 4 weeks for 52 weeks (CheckMate 23810 and US FDA label)
• Pembrolizumab 200 mg iv once every 3 weeks for 52 weeks (EORTC 13259)
• Dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily for 52 weeks (COMBI-AD11)